Pina-Cabral L, Santos L, Mesquita B, Amaro T, Magalhães S, Criado B
Instituto Politécnico de Saúde do Norte (IPSN), CESPU, CRL, Famalicão, Portugal.
Clin Transl Oncol. 2007 Nov;9(11):731-6. doi: 10.1007/s12094-007-0130-4.
The aim of the present study was to assess if the presence of survivin mRNA in exfoliated cells present in urine samples can be a reliable marker of the presence of bladder tumour and recurrence.
Urine samples from 30 patients with superficial urothelial cell carcinomas (UCC) were collected prior to transurethral resection (TUR) of the tumour and in the first routine follow-up, three months after TUR. Detection of survivin mRNA was performed by reverse transcription-polymerase chain reaction (RT-PCR).
No correlation was observed between survivin detection and the clinicopathological variables analysed, nevertheless, when patients were grouped into low-grade (G1) and high-grade (G2+G3) tumours, statistically significant differences were found between both groups (p=0.04). When we analysed the results of survivin detection and urinary cytology together, we observed that informative cases rose from 27.8% to 44.4%. Also, Kaplan-Meier curves for patients with negative cytology in the first followup, categorised according to survivin detection, revealed that survivin mRNA positive cases recurred earlier than negative ones.
From our results we can conclude that detection of survivin expression can be a reliable tumour marker, but more studies are needed to clarify the potential of survivin to predict recurrences. These results showed that survivin detection in combination with conventional urinary cytology can be a useful tool to increase the sensitivity in detecting the presence of a recurrence after TUR.
本研究的目的是评估尿液样本中脱落细胞中生存素mRNA的存在是否可作为膀胱肿瘤存在及复发的可靠标志物。
收集30例浅表性尿路上皮癌(UCC)患者在肿瘤经尿道切除术(TUR)前及TUR后三个月首次常规随访时的尿液样本。通过逆转录聚合酶链反应(RT-PCR)检测生存素mRNA。
生存素检测与所分析的临床病理变量之间未观察到相关性,然而,当将患者分为低级别(G1)和高级别(G2+G3)肿瘤时,两组之间存在统计学显著差异(p=0.04)。当我们一起分析生存素检测结果和尿液细胞学结果时,发现信息性病例从27.8%增加到44.4%。此外,根据生存素检测对首次随访时细胞学阴性的患者绘制的Kaplan-Meier曲线显示,生存素mRNA阳性病例比阴性病例复发更早。
从我们的结果可以得出结论,生存素表达的检测可以是一种可靠的肿瘤标志物,但需要更多研究来阐明生存素预测复发的潜力。这些结果表明,生存素检测与传统尿液细胞学相结合可以成为提高TUR后复发检测敏感性的有用工具。